Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 7;6(8):1684–1697. doi: 10.1002/sctm.17-0078

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Modulation of platelets by SCE therapy in diabetic patients. (A–C): Clinical data were summarized from the clinical trials in Chinese diabetic subjects. Both T1D (N = 10) and T2D (N = 16) received one treatment with SCE therapy. A complete blood count (CBC) test was performed at baseline (before the treatment) and 1 month after the treatment with SCE therapy. Age‐ and gender matched T1D (N = 7) and T2D (N = 10) subjects receiving conventional therapy served as controls. (A): Increase in the platelet count. (B): Increase in the platelet distribution width (PDW). (C): Decrease in the mean platelet volume (MPV). (D): Increase in the platelet count of Caucasian T1D subjects after receiving one treatment with SCE therapy, N = 8. Data are presented as mean ± SD.